Philippines
orders Dengvaxia market pullout
MANILA - The Food and Drug
Administration said it ordered Sanofi Pasteur to suspend the sale of its dengue
vaccine after the French drug-maker admitted that it could cause a more severe
case of the disease in some instances.
Sanofi should "SUSPEND the
sale/distribution/marketing and cause the WITHDRAWAL" of Dengvaxia, until
it complies with regulators' orders, the FDA said in an advisory late Monday.
The company last week said that
if Dengvaxia is administered to those who have not had the mosquito-borne illness
before, it could cause "more cases of severe disease," prompting
the government to suspend its public immunization program.
The vaccine however remained
available on an individual basis in consultation with doctors until the FDA
order late on Monday.
The FDA has also directed Sanofi
to mount an information campaign through advisories, letters to doctors and
patient fora.
The agency urged the public to
report any incident that "reasonably indicates that Dengvaxia has caused
or contributed to the death, serious illness, or serious injury."
Sanofi had said that Dengvaxia
would not cause anyone who was immunized to die and that potential cases of
"severe dengue" would not be fatal.
"What is this severe
(dengue)? When people think of 'severe', this already includes dengue shock
that could lead to death, but no," Sanofi Pasteur regional head for dengue
Joselito Sta. Ana told reporters on Monday.
Sanofi's definition of
"severe dengue" merely referred to symptoms including 2 days of
fever, a lower platelet count and bruising, said Sta. Ana.
Presidential spokesman Harry
Roque also allayed the public's fears, saying there was "no danger"
with the vaccine.
"The worst that can happen
is for those who have not had dengue before -- which is 1 out of 10 (Filipinos)
-- they may get infected with dengue but falling under our previous
classification of 'mild', having fever and bruises," Roque said.
The Department of Justice said
Monday that the National Bureau of Investigation would investigate the vaccination
program "over the alleged danger to public health." It warned in a
statement that charges could follow.
The administration of former
President Benigno Aquino launched the vaccination program in 2016, making the
Philippines the first nation to use Dengvaxia on a mass scale. Some 733,000
people had been immunized under the initiative. With Agence France-Presse
No comments:
Post a Comment
Note: only a member of this blog may post a comment.